This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

GnRH analogues

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Luteinising hormone releasing hormone agonists (also called gonadotropin-releasing hormone agonists GnRH agonists) are agents used in the hormonal modulation of malignant and benign diseases including:

  • prostatic carcinoma
  • breast carcinoma
  • endometriosis

These agents may cause an initial stimulation in the secretion of luteinising hormone (LH) resulting in a "flare" in symptoms in patients with symptomatic prostatic cancer during the first 1-2 weeks of treatment.

After 1-2 weeks pituitary gonadotrophin secretion is down-regulated leading to inhibition of ovarian and testicular sex hormone production.

If a tumour flare is likely to cause problems e.g. spinal cord compression, then an antiandrogen should also be given at least 3 days before the LHRH agonist and continued concurrently for three weeks.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.